Contact:
4008465777
-
About Us
News & Events
-
02-27
Partnership | Dongbao Pharm and Huisheng Pharm Enter into a Partnership to Further Enrich Their Product Portfolio
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or the "Company") signed a "Commercialization Cooperation Agreement" (the "Agreement") with Huisheng Biopharmaceuticals Co., Ltd. ("...
-
02-27
GLP-1 Global Expansion | Dongbao Pharm Receives a GMP Certificate from Brazil for Its Liraglutide Injection
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or the "Company") officially received a Good Manufacturing Practice (GMP) certificate for its liraglutide injection, jointly develop...
-
11-29
Breakthrough in GLP-1 Global Expansion | Tonghua Dongbao's Liraglutide Injection Approved for Marketing in Peru
Recently, a liraglutide injection, developed by Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") and its partner, Kexing Biopharm Co., Ltd. ("Kexing Biopharm"), has been a...
-
11-26
Global Expansion | Tonghua Dongbao's Liraglutide Injection Passes the On-Site GMP Audit by ANVISA
Recently, a liraglutide injection, developed by Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") and its partner, Kexing Biopharm Co., Ltd. ("Kexing Biopharm"), has passed...
-
11-14
Global Expansion | Tonghua Dongbao's Insulin Aspart Injection Approved for Marketing in the Dominican Republic
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") recently received marketing approval for its Insulin Aspart Injection from the Ministry of Public Health and Social Welfare of the Dominican Re...
-
10-25
Global Expansion | Tonghua Dongbao's Insulin Aspart Injection Approved for Marketing in Indonesia
Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") recently received a drug registration certificate for its insulin aspart injection, issued by the Indonesian Food and Drug...